Sign In
Buy PHIO
$1.11
-0.0100 (-0.89%)
At Close: Jun 03, 2026
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
07:00am, Tuesday, 26'th May 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - May 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical
Live virtual fireside chat - investors, advisors, and life sciences analysts invited to attendFeaturing Dermatologist Mary Spellman, M.D., with Phio
Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
04:05pm, Thursday, 07'th May 2026
Completion of Lead Clinical Candidate PH-762 Dose Escalation Trial for Treatment of Skin Cancer with Favorable Safety and Pathology Data Key Development Agreements Secured for Nonclinical Toxicology a
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
07:00am, Thursday, 23'rd Apr 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - April 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical
Phio invites investors, advisors and analysts with an interest in the life sciences sector to attend this virtual event R. Todd Plott, M.D.
Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026
07:00am, Thursday, 09'th Apr 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - April 9, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical
Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762
07:00am, Monday, 30'th Mar 2026
A Critical Next Step in Advancing Phio's PH-762 Program to Treat Cutaneous Carcinomas King of Prussia, Pennsylvania--(Newsfile Corp. - March 30, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a
Financial Analysis: Galectin Therapeutics (NASDAQ:GALT) & Phio Pharmaceuticals (NASDAQ:PHIO)
02:52am, Friday, 27'th Mar 2026
Phio Pharmaceuticals (NASDAQ: PHIO - Get Free Report) and Galectin Therapeutics (NASDAQ: GALT - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contr
Head-To-Head Contrast: ProKidney (NASDAQ:PROK) & Phio Pharmaceuticals (NASDAQ:PHIO)
02:19am, Friday, 27'th Mar 2026
Phio Pharmaceuticals (NASDAQ: PHIO - Get Free Report) and ProKidney (NASDAQ: PROK - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two b
Prestigious Late-Breaking Research Session Positions PH-762 as a Promising New PD-1 Directed Immunotherapy Candidate on March 28, 2026 at 3 PM (MDT) King of Prussia, Pennsylvania--(Newsfile Corp. - Ma
Phio Pharmaceuticals (PHIO) Projected to Post Earnings on Monday
01:42am, Monday, 23'rd Mar 2026
Phio Pharmaceuticals (NASDAQ: PHIO - Get Free Report) is projected to issue its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($0.3
Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office
11:30am, Monday, 16'th Mar 2026
Registration link below for Wednesday March 18, 2026 at 4 PM EDT Phio invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT
08:35am, Tuesday, 10'th Mar 2026
The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorC
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT
07:59am, Tuesday, 10'th Mar 2026
The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorC
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT
07:00am, Tuesday, 10'th Mar 2026
The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorC
